GleamWall
中文EN

CSCIF COSCIENS Biopharma Inc. IFRS

Perfumes, Cosmetics & Other Toilet Preparations · OTC · SEC CIK 1113423 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-21.8%
TTM net income YoY32.3%
TTM EPS YoY44.9%
Revenue 3-yr CAGR-19.9%
Net income 3-yr CAGR—

Margins

Gross margin35.3%
Operating margin-142.5%
Net margin-138.1%
FCF margin-122.4%
EBITDA margin-126.6%

Returns

ROE-121.8%
ROA-36.7%
ROIC (approx.)—
Asset turnover0.27x

Leverage & solvency

Liabilities / assets82.1%
Debt / equity0.00x
Current ratio3.18x
Interest coverage-63.58x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue9.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$7.50M$9.59M
Cost of revenue$4.85M$4.86M
Gross profit$2.65M$4.73M
R&D expense$2.95M$8.30M
SG&A expense$10.06M$10.45M
Operating income-$10.68M-$18.28M
Interest expense$168,000$129,000
Pretax income-$10.35M-$15.22M
Income tax$10,000$84,000
Net income-$10.36M-$15.31M
EBITDA-$9.49M-$16.67M
EPS (basic)-3.27-5.93
EPS (diluted)-3.27-5.93
Weighted avg. shares (diluted)3.17M2.58M
Balance sheet
Cash & equivalents$7.31M$16.39M
Receivables$1.26M$2.36M
Inventory$1.31M$2.69M
Current assets$11.50M$23.98M
PP&E, netmay include right-of-use assets (IFRS)$9.81M$10.97M
Total assets$21.43M$35.07M
Current liabilities$3.61M$7.22M
Total liabilities$17.59M$21.91M
Shareholders' equity$3.84M$13.16M
Cash flow statement
Operating cash flow-$8.47M-$14.57M
Capital expenditure$706,000$1.16M
Free cash flow-$9.18M-$15.73M
Investing cash flow-$458,000$25.08M
Financing cash flow-$407,000-$588,000
Depreciation & amortization$1.19M$1.61M
Stock-based compensation-$12,000$464,000

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.